TAPI (TEVA Active Pharmaceutical Ingredients)

TAPI (TEVA Active Pharmaceutical Ingredients)

TAPI (Teva Active Pharmaceutical Ingredients)

TAPI is an international supplier of active pharmaceutical ingredients, with more than $1.9 Billion in annual sales. TAPI employs over 4,600 professionals worldwide and boasts a portfolio of over 290 active pharmaceutical ingredients.  TAPI is a stand alone business unit within Teva Pharmaceutical Industries Limited and as its mother company is headquartered in Israel.  TAPI’s customers are leading generic & innovative pharmaceutical manufacturers.

Teva API division (TAPI) manufactures over 315 different API’s covering various therapeutic categories, and have registered 226 US-DMF’s as well as 83 EDQM COS’s up till date. TAPI group factories include well known names in the global pharmaceutical landscape, such as:

  • IVAX (Czech Republic)
  • Sicor (Italy, Mexico)
  • Pliva (Croatia)
  • TPW Biogal (Hungary)
  • PFC (Italy)

All the TAPI group factories are fully regulated and approved by global regulatory authorizations such as the US-FDA, MHRA and others.


LGM and TAPIIn continuation with our efforts to bring only the finest quality API’s to our clients while minimizing any regulatory problems and quality issues, we are delighted to inform you that our company LGM Pharma has now been selected as the Sole Distributor of Teva for their extensive API portfolio, for the US pharmacy compounding market.

TAPI are widely recognized as the world-leader in terms of their API production, excellent GMP quality assurance and extensive regulatory position. We at LGM Pharma are proud to be able to bring to you all of these advantages!

Please do not hesitate to contact us for any API’s that are produced by any of the TAPI group factories – Teva, IVAX, Sicor, Pliva and others, and we will be glad to be in touch for any price quotations that may be required.

View our TAPI products, our agency appointment letter, and our TAPI Products PDF.


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1).  Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service